169 related articles for article (PubMed ID: 8890801)
1. Effect of a mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutriments.
De Lorgeril M; Salen P; Martin JL; Mamelle N; Monjaud I; Touboul P; Delaye J
J Am Coll Cardiol; 1996 Nov; 28(5):1103-8. PubMed ID: 8890801
[TBL] [Abstract][Full Text] [Related]
2. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.
Hueb W; Lopes NH; Gersh BJ; Soares P; Machado LA; Jatene FB; Oliveira SA; Ramires JA
Circulation; 2007 Mar; 115(9):1082-9. PubMed ID: 17339566
[TBL] [Abstract][Full Text] [Related]
3. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W; Forder P; Simes J; Hunt D; Tonkin A;
Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
Knopp RH; d'Emden M; Smilde JG; Pocock SJ
Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
[TBL] [Abstract][Full Text] [Related]
5. Mediterranean diet and reduction in the risk of a first acute myocardial infarction: an operational healthy dietary score.
Martínez-González MA; Fernández-Jarne E; Serrano-Martínez M; Marti A; Martinez JA; Martín-Moreno JM
Eur J Nutr; 2002 Aug; 41(4):153-60. PubMed ID: 12242583
[TBL] [Abstract][Full Text] [Related]
6. [Cardiovascular risk factors and prevention in women: similarities and differences].
Sclavo M
Ital Heart J Suppl; 2001 Feb; 2(2):125-41. PubMed ID: 11255880
[TBL] [Abstract][Full Text] [Related]
7. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
8. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.
Mehta SR; Yusuf S;
Eur Heart J; 2000 Dec; 21(24):2033-41. PubMed ID: 11102254
[TBL] [Abstract][Full Text] [Related]
9. The relationship between adherence to the Mediterranean diet and the severity and short-term prognosis of acute coronary syndromes (ACS): The Greek Study of ACS (The GREECS).
Panagiotakos DB; Arapi S; Pitsavos C; Antonoulas A; Mantas Y; Zombolos S; Stefanadis C
Nutrition; 2006; 22(7-8):722-30. PubMed ID: 16730948
[TBL] [Abstract][Full Text] [Related]
10. The Mediterranean diet in secondary prevention of coronary heart disease.
de Lorgeril M; Salen P
Clin Invest Med; 2006 Jun; 29(3):154-8. PubMed ID: 17058434
[TBL] [Abstract][Full Text] [Related]
11. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network.
Giannuzzi P; Temporelli PL; Marchioli R; Maggioni AP; Balestroni G; Ceci V; Chieffo C; Gattone M; Griffo R; Schweiger C; Tavazzi L; Urbinati S; Valagussa F; Vanuzzo D;
Arch Intern Med; 2008 Nov; 168(20):2194-204. PubMed ID: 19001195
[TBL] [Abstract][Full Text] [Related]
12. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.
de Lorgeril M; Salen P; Martin JL; Monjaud I; Delaye J; Mamelle N
Circulation; 1999 Feb; 99(6):779-85. PubMed ID: 9989963
[TBL] [Abstract][Full Text] [Related]
13. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
[TBL] [Abstract][Full Text] [Related]
14. [Alpha-linolenic acid, cardiovascular disease and sudden death].
Landmark K; Alm CS
Tidsskr Nor Laegeforen; 2006 Nov; 126(21):2792-4. PubMed ID: 17086218
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; Jablonski KA; Rice MM; Warnica JW; Domanski MJ; Hsia J; Gersh BJ; Rifai N; Ridker PM; Pfeffer MA; Braunwald E;
Circulation; 2007 Mar; 115(12):1528-36. PubMed ID: 17372173
[TBL] [Abstract][Full Text] [Related]
16. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis.
Berger JS; Brown DL; Becker RC
Am J Med; 2008 Jan; 121(1):43-9. PubMed ID: 18187072
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
Bartolucci AA; Howard G
Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
[TBL] [Abstract][Full Text] [Related]
18. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
Brugts JJ; Boersma E; Chonchol M; Deckers JW; Bertrand M; Remme WJ; Ferrari R; Fox K; Simoons ML;
J Am Coll Cardiol; 2007 Nov; 50(22):2148-55. PubMed ID: 18036453
[TBL] [Abstract][Full Text] [Related]
19. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).
Fox KM; Henderson JR; Bertrand ME; Ferrari R; Remme WJ; Simoons ML
Eur Heart J; 1998 Sep; 19 Suppl J():J52-5. PubMed ID: 9796841
[TBL] [Abstract][Full Text] [Related]
20. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
Wilcox R; Kupfer S; Erdmann E;
Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
